Are there differences in efficacy of ramucirumab + pembrolizumab based on extent and duration of response to first line chemo/pembro?

S1800A required that patients have at least 84 days (~4 cycles) of time on treatment before progression on anti-PD-L1 therapy. This will exclude patients who had rapid progression. Other than this entry criterion for all patients, the trial stratified by PD-L1 status, but did not select for prior IC...

S1800A did not report treatment outcomes according to response to prior ICI therapy. Generating the data would be helpful to understand which patient populations might benefit most from the pembrolizumab plus ramucirumab combination, though the interpretation may be limited by small sample size.

Whil...

The trial requires all patients to have been on immune checkpoint inhibitor (ICI) therapy for 84 days or more so the findings are unique to acquired resistance. In the subset analysis of OS, we saw a more pronounced benefit in those who had received chemotherapy followed by ICI therapy which is a su...